Sonia Jiménez-Baranda, … , Inês Pires Silva, Nina Bhardwaj
Citation Information: J Clin Invest. 2012;122(2):481-484. https://doi.org/10.1172/JCI61345.
Sonia Jiménez-Baranda, … , Inês Pires Silva, Nina Bhardwaj
Published January 17, 2012
Citation Information: J Clin Invest. 2012;122(2):481-484. https://doi.org/10.1172/JCI61345.
Abstract
Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.
Authors
Sonia Jiménez-Baranda, Inês Pires Silva, Nina Bhardwaj
Full Text PDF | Download (592.18 KB)
Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)